Sequentia Biotech, a Barcelona bioinformatics company founded in 2013, says it has completed more than 800 data analysis projects for clients in 63 countries. With EU money it built MICK, a platform that analyses microbiome sequencing data automatically and gives doctors recommendations without any coding.
The European Innovation Council granted €2,156,682 towards a €3.08 million project that ran from September 2022 to February 2025. In September 2024 Sequentia raised €10 million led by Seventure Partners with the EIC Fund. In April 2026 its gut pathogen module, MICK Clinical, received a CE-IVD mark under the EU's In Vitro Diagnostic Regulation.
Company file
- Legal entity
- Sequentia Biotech SL, Barcelona, Spain
- Founded
- January 2013
- CEO
- Walter Sanseverino, co-founder
- Products
- MICK microbiome platform, MICK Clinical, bioinformatics services
- Investors
- Seventure Partners, EIC Fund
- Certification
- ISO 13485; CE-IVD under IVDR for MICK Clinical
- EIC project
- MICK, 1 Sep 2022 to 28 Feb 2025, closed
- EIC funding
- Blended finance
Where Sequentia Stands Today
Spanish register data compiled by Empresia show Sequentia active with 25 employees, annual sales above €2.5 million and capital increases in July 2024, August and September 2025 and May 2026. In May 2025 it announced a partnership with BatchX, a cloud platform for running bioinformatics tools, and in 2026 it published an analytical validation of AIR, its RNA sequencing analysis software. It has not named hospitals that use MICK Clinical in routine care.
The Technology: Reading the Gut From Sequencing Data
According to the CORDIS report, MICK is "the first platform to offer real-time, automated microbiome analysis, providing evidence-based recommendations for personalized patient care". The project profiled dysbiosis, an imbalance of gut microbes, in line with clinical guidelines, ran pilot studies with hospitals and validated the pathogen detection module to IVDR standards. The certified MICK Clinical is software that screens sequencing data for gastrointestinal bacterial pathogens; it was validated at Vall d'Hebron University Hospital in Barcelona.
"This CE-IVD achievement marks a critical transition from innovation to clinical adoption."
Isabelle de Cremoux, CEO of Seventure Partners, April 2026What the EIC Project Promised, and What CORDIS Shows
The project promised a "translational microbiome platform". CORDIS reports ISO 13485 implemented, IVDR technical documentation and risk analysis completed, and a pathogen module with "96.2% sensitivity and 100% specificity in validation". The certification announcement gives lower figures, 91.7% sensitivity and 99.5% specificity; neither source explains the difference.
- A working platformDeliveredBuilt, per CORDIS.
- Clinical validationDeliveredVall d'Hebron study.
- IVDR certificationDeliveredCE-IVD, April 2026.
- Hospital adoptionNot shownNo named clinical users.
What Has Happened Since the Award
The Money
The award was blended finance, and the EIC Fund co-invested in the September 2024 Series A of €10 million led by Seventure Partners. The split between the two investors is not public. The CEO said at the time that the money would "accelerate adoption of MICK globally".
What cannot be checked
How much of Sequentia's revenue comes from MICK rather than its service business, which hospitals pay for MICK Clinical and the EIC Fund's stake are not public.
Why Europe Should Care
Diagnostic software sold in the EU must be certified under the In Vitro Diagnostic Regulation. Sequentia used EIC grant and equity money to get there, turning a bioinformatics service company into the maker of a certified diagnostic product.
What the project promised
A translational microbiome platform for clinical use.
What the record shows
A CE-IVD-marked pathogen module, €10M raised with the EIC Fund and a 25-person company.
The Verdict
Certified, now it must sell
Sequentia delivered what the EIC funded: a validated, certified platform. What it has not yet shown is hospitals using MICK Clinical routinely, and its two sets of accuracy figures need explaining.
Sequentia Biotech has not been asked for comment for this article. It is based entirely on company statements, EU project data and Spanish register information, linked throughout.
